All In Biotech

NDA 208194 · Eagle Pharms

Bendeka

Bendamustine Hydrochloride · Intravenous

Orphan

Last checked: Nov 20, 2026Latest source record: Jan 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Dec 7, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

426

81 Phase 3, 51 recruiting

FAERS reports

8,502

7,847 serious, 1,611 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 19, 2024.

BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Mechanism: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 7, 2015 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
  • BENDEKA · BENDAMUSTINE HYDROCHLORIDE 100MG/4ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bendamustine" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,047
  • pyrexia581
  • disease progression512
  • covid-19412
  • drug ineffective405
  • product use in unapproved indication404
  • febrile neutropenia378
  • malignant neoplasm progression363
  • neutrophil count decreased360
  • neutropenia358
  • pneumonia350
  • platelet count decreased349

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20093
20102
201115
2012129
201346
2014267
2015423
2016544
2017484
2018687
2019624
2020675
2021771
20221,484
20231,043
2024755
2025316
2026233

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bendeka (Bendamustine HCl)

2024 spending

$1.5M

Beneficiaries

53

169 claims

Per beneficiary

$27,927

$591.12 per unit

View as table
YearSpending
2020$2,948,904
2021$3,152,118
2022$3,089,328
2023$3,353,063
2024$1,480,157

Part B: Bendeka (Bendamustine HCL) · HCPCS J9034

2024 spending

$56.2M

Beneficiaries

4,066

23,256 claims

Per beneficiary

$13,832

2024 ASP limit $13.79 per unit

View as table
YearSpending
2020$148,578,693
2021$120,158,191
2022$104,836,511
2023$81,666,046
2024$56,240,756

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 385 on PubMed

Sponsor: Eagle Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.